IMMUNOGENICITY AND SAFETY OF A THREE-DOSE SARS-COV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY

Kristin Hammersbøen Bjørlykke  ¹     Ingrid Jyssum  ²     Anne Therese Tveter  ²     Joseph Sexton  ²     Ingrid E. Christensen  ²     Trung T. Tran  ³     Siri Mjaaland  ⁴     David J. Warren  ⁴     Tore K Kvien  ⁴     Adity Chopra  ⁴     Grete Birkeland Kro  ⁴     Jørgen Jahnsen  ⁴     Ludvig A. Munthe  ⁴     Espen A Haavardsholm  ⁴     Gunnveig Grødeland  ⁴     John Torgils Vaage  ⁴     Sella Aarrestad Provan  ⁴     Guro Løvik Goll  ⁴     Silje Watterdal Syversen  ⁴     Kristin Kaasen Jørgensen  ^4    
1 Akershus University Hospital, Lørenskog, Norway
² Diakonhjemmet Hospital, Oslo, Norway
³ Oslo University Hospital, Oslo, Norway
⁴ Norwegian Institute of Public Health, Oslo, Norway

Topic
IBD, Nurses, Primary Care

Session
COVID-19 still here: Lessons and questions

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)